Thelansis

Developmental and Epileptic Encephalopathies (DEEs) Market Outlook Thelansis’s “Developmental and Epileptic Encephalopathies (DEEs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Developmental and Epileptic Encephalopathies (DEEs) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and pat...

  Developmental and Epileptic Encephalopathies (DEEs) Market Outlook Thelansis’s “Developmental and Epileptic Encephalopathies (DEEs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Developmental and Epileptic Encephalopathies (DEEs) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Developmental and Epileptic Encephalopathies (DEEs) Overview Developmental and epileptic encephalopathies (DEEs) are a heterogeneous group of broad electroclinical syndromes characterized by epilepsy, developmental delay or regression, or intellectual disability, an abnormal EEG, and other possible neurological or systemic manifestations. DEEs are cla...

Developmental and epileptic encephalopathies (DEEs) are a heterogeneous group of broad electroclinical syndromes characterised by epilepsy, developmental delay or regression or intellectual disability, an abnormal EEG, and other possible neurological or systemic manifestations. DEEs are classically considered pediatric disorders as most of the phenotypes are identified in children. Clinical data suggest that neurodevelopmental impairment in classical epileptic encephalopathies starts before epilepsy onset and progresses after epilepsy remission; DEEs consider that epileptic activity in classical epileptic encephalopathies plays only a partial or limited role in the neurodevelopment of the patient. It is established that epilepsy is more an epiphenomenon of the etiological process and the abnormal neurodevelopmental trajectory, which plays the leading role in the pathophysiological process. In most cases, patients remain undiagnosed due to insufficient genetic testing; an estimated 50% ...